Literature DB >> 9600818

Single-dose dexamethasone paclitaxel premedication.

J P Micha1, M A Rettenmaier, R Dillman, P Fraser, C Birk, J V Brown.   

Abstract

Paclitaxel is one of the most active chemotherapy agents for the treatment of ovarian and other gynecologic cancers. Hypersensitivity reactions (HSR) remain one of the major clinical concerns in the use of paclitaxel. This report deals with 183 consecutive patients treated with paclitaxel chemotherapy. A total of 1010 cycles were administered. Premedication consisted of single-dose intravenous decadron, benadryl, and cimetidine administered immediately prior to chemotherapy. Four hypersensitivity reactions occurred. All patients recovered uneventfully from these reactions. Two of these patients received additional oral decadron followed by the standard premedication and were successfully retreated with multiple courses of paclitaxel therapy without reaction. Our findings confirm other reports that paclitaxel chemotherapy hypersensitivity reactions can be decreased with a single-dose intravenous decadron premedication regimen and that patients who do have paclitaxel HSRs may be safely retreated with paclitaxel. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9600818     DOI: 10.1006/gyno.1998.4993

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

Review 1.  Diagnostic tools for hypersensitivity to platinum drugs and taxanes: skin testing, specific IgE, and mast cell/basophil mediators.

Authors:  Joana Caiado; Matthieu Picard
Journal:  Curr Allergy Asthma Rep       Date:  2014-08       Impact factor: 4.806

2.  Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy.

Authors:  Napa Parinyanitikul; Walailuk Tanpipattanakul; Nattaya Poovorawan; Thanapoom Rattananupong; Poranee Laoitthi; Piyada Sithidetphaiboon; Suebpong Thanasanvimon; Virote Sriuranpong
Journal:  Support Care Cancer       Date:  2018-02-12       Impact factor: 3.603

3.  Oxaliplatin is a safe alternative option for patients with recurrent gynecologic cancers after hypersensitivity reaction to Carboplatin.

Authors:  Nonna V Kolomeyevskaya; Shashikant B Lele; Austin Miller; Grazyna C Riebandt; Bonnie L Blum; Kunle O Odunsi; Peter J Frederick
Journal:  Int J Gynecol Cancer       Date:  2015-01       Impact factor: 3.437

4.  Pre-medication protocols for the prevention of paclitaxel-induced infusion related reactions: a systematic review and meta-analysis.

Authors:  Samuel Dubinsky; Deep Patel; Xiang Wang; Amirrtha Srikanthan; Terry L Ng; Corey Tsang
Journal:  Support Care Cancer       Date:  2022-02-12       Impact factor: 3.603

Review 5.  Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review.

Authors:  Matthieu Picard; Mariana C Castells
Journal:  Clin Rev Allergy Immunol       Date:  2015-10       Impact factor: 8.667

6.  Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens.

Authors:  J S Kloover; M A den Bakker; H Gelderblom; J P van Meerbeeck
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.